Analyst Ratings for Beam Therapeutics
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Cantor Fitzgerald Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $62
Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Overweight rating and announces Price Target of $62.
Beam Therapeutics Reports Progress Across Base Editing Portfolio And Outlines Key Anticipated Milestones
BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023
First Patient Dosing in BEAM-201 Trial in Patients with
Cathie Wood Gets Elon Musk’s Attention Over Gene-Editing Therapy Potential: ‘Investors Chased The Dream Then. Now, They’re Running Away’
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.
4 Analysts Have This to Say About Beam Therapeutics
Analysts have provided the following ratings for Beam Therapeutics (NASDAQ:BEAM) within the last quarter: Bullish Somewhat Bullish Indifferent…
Analyst Beefs Up Beam Therapeutics Price Target, Says ‘Reward Is Now Skewed To Upside’
BMO Capital Markets has upgraded Beam Therapeutics Inc (NASDAQ:BEAM) from Market Perform to Outperform and raised the price target from $61 to…
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close at $114.92 on Friday.
BMO Capital Upgrades Beam Therapeutics to Outperform, Raises Price Target to $66
BMO Capital analyst Kostas Biliouris upgrades Beam Therapeutics (NASDAQ:BEAM) from Market Perform to Outperform and raises the price target from $61 to $66.
Benzinga’s Top Ratings Upgrades, Downgrades For December 13, 2022
Upgrades For Equinix Inc (NASDAQ:EQIX), Cowen & Co. upgraded the previous rating of Market Perform to Outperform. In…
Citigroup Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $62
Citigroup analyst Samantha Semenkow initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $62.